Kuros reports success in clinical study

KUR-023 is a synthetic hydrogel-based sealant that utilises Kuros' synthetic technology. The product candidate is administered as a spray with the aim of ensuring water-tight closure of sutured incisions through the dura mater following cranial surgery.  It is intended to be used as an adjunct to normal closure techniques such as suturing.
 
The trial was a European, single arm, multi-center study in which 41 patients were treated. The primary endpoint was the prevention of intra-operative leakage. The secondary endpoints related to safety and further effectiveness assessments.  In all evaluable patients a single application of KUR-023 was sufficient to seal the intra-operative leakage. The safety and further effectiveness assessments were equally positive.
 
Virginia Jamieson, Chief Medical Officer of Kuros commented: “These results in combination with positive feedback from the neurosurgeons are highly encouraging. Achieving water-tight closure of the dura following cranial surgery is important to both surgeons and patients, and KUR-023 has demonstrated its ability to meet this need.”
 
Didier Cowling, Chief Executive Officer of Kuros, commented: “The results from this study have demonstrated that KUR-023 is a highly effective dural sealant. We now look forward to progressing this product to market in the EU.”

Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, spine and wound indications. Kuros’ has a diverse pipeline of product candidates with its most advanced product candidates being in trauma and wound care. Since its creation, Kuros has received over $200 million in funding. The company is located in Zurich, Switzerland.